UKKi024-B
Donor information | |
|---|---|
| Gender: | Male |
| Age: | 30-34 |
| Ethnicity: | Caucasian / european |
Disease status | |
| Disease: |
Brugada syndrome
Genetic testing of the patient was not performed |
| Affected: | Yes |
| Family history: | Death from heart disease of the uncle |
| Clinical information: | Electrocardiogram typical for patients with Brugada syndrome type 1, asympthomatic demasking in ajmalin test |
General information | |
| Depositor: | Klinikum der Universität zu Köln |
| Cell line name: | UKKi024-B |
| Cell line alternative names: | NP0133-1 |
| Biosamples ID: | SAMEA17635168 |
| hPSCreg name: | UKKi024-B |
| Derivation country: | Germany |
Related lines | |
| From the same donor: | UKKi024-A, UKKi024-C |
-
Derivation
Derivation
Primary cell type: Peripheral blood mononuclear cell Tissue collection year: 2016 Passage number reprogrammed: 0 Reprogramming method
Vector type: Non-integrating Vector: Sendai virus Gene list: - KLF4
- MYC
- POU5F1
- SOX2
Is the reprogramming vector detectable: No Merthods used: pcr Notes on reprogramming vector detection: sendai virus absent Files showing reprogramming vector expressed or silenced: Image / Result Derivation
Xeno free conditions: no Derived under gmp: no Available as clinical grade: no -
Culture conditions
Culture Conditions
Medium: - Passage method: - Matrix: - CO2 concentration: - O2 concentration: - Temperature: - -
Characterization
-
Genotyping
Genotyping
Karyotyping
Passage number: 32 Cell line karyotype: No larger chromosomal aberrations observed Karyotyping method: Molecular karyotyping by SNP array Image / Result Genotyping
STR/Fingerprinting: A 16 allele profile has been recorded and data is available upon request, after cell line purchase.
At European Collection of Authenticated Cell Cultures (ECACC)
In stock
Cell Line Information Pack
A Cell Line Information Pack (CLIP) is created to communicate cell line specific information relating to restrictions on use to a user accessing cell lines from EBiSC. A CLIP contains information about a cell line including any specific third party obligations (TPOs) relating to, for example, intellectual property (IP) or the donor consent which affect the use of the cell line.